Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;39(2):210-4.
doi: 10.1111/jcpt.12129. Epub 2014 Jan 10.

Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan

R Shimazawa  1 , M Ikeda
Affiliations

Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan

R Shimazawa et al. J Clin Pharm Ther. 2014 Apr.

Abstract

What is known and objectives: In vitro companion diagnostic devices (CDx) provide information on pharmacogenomic biomarkers (PGBMs) to enable the safe and effective use of targeted agents for personalized therapy. These devices require specific regulations that strike a balance between scientific evidence and financial burden. The aims were to compare approval of PGBMs and CDx in the USA and Japan and to help inform current discussions on personalized medicine.

Methods: We analysed published documentation from the USA and Japan for CDx and PGBMs, listed by the US Food and Drug Administration (FDA). Aspects evaluated were aim, approval state and therapeutic area. Coverage by the National Health Insurance in Japan was also investigated.

Results and discussion: Thirty-eight PGBMs were listed in the FDA table as of March 2013. In the USA, the aim was efficacy in 55% (21/38). The largest therapeutic area was oncology (39%, 15/38). Fifty-three per cent (20/38) of the PGBMs had a corresponding CDx approved. Of the 38 PGBMs in the FDA table, six had no approved drug in Japan; in 16 of the remaining 32 PGBMs, the aim was efficacy. The largest therapeutic area was oncology (34%, 11/32). Of the 32 PGBMs, 15 were associated with an approved and/or covered CDx, with only 11 having an approved CDx. Four PGBMs had a covered CDx without prior approval in Japan.

What is new and conclusion: Our study confirms that there is still a substantial gap in the approval of PGBMs and CDx between Japan and the USA. Complementary coverage of unapproved CDx by the National Health Insurance, however, is raising access to a similar level in both countries. Because the number of expensive personalized medicines and CDx is increasing, patient access will continue to be an important challenge to healthcare systems in all countries.

Keywords: USFDA; biomarkers; drug approval; in vitro diagnostic devices; personalized medicine; pharmacogenomics.

PubMed Disclaimer

References

    1. Li-Wan-Po A. Pharmacogenetics and personalized medicine. J Clin Pharm Ther. 2012;37:617–619. - PubMed
    1. Shimazawa R, Ikeda M. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan. J Clin Pharm Ther. 2013;38:468–475. - PubMed
    1. Shimazawa R, Ikeda M. Are there any differences in the regulations of personalised medicine among the US, EU, and Japan? Br J Clin Pharmacol. 2013;75:1365–1367. - PMC - PubMed
    1. U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labels. Available at: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/... (accessed 5 March 2013)
    1. U.S. Food and Drug Administration. Draft Guidance for Industry and Food and Drug Administration Staff – In Vitro Companion Diagnostic Devices. Available at: http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedo... (accessed 23 September 2013)

Publication types